Showing results (1-10 of 60) with videos related to
Sort By:
Pageof 6
Annals of Internal Medicine|May 6, 2024
In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs varyClare O'Brien, Sean F DinneenAnnals of Internal Medicine|January 2, 2023
In T1DM, open-source automated insulin delivery increased glucose time in target vs. sensor-augmented pumpsMichael Lockhart, Sean F DinneenAnnals of Internal Medicine|January 1, 2024
In latent autoimmune diabetes in adults, mortality was similar to T2DM but retinopathy was higher at 5.9 yCaoimhe Casey, Sean F DinneenAnnals of Internal Medicine|July 3, 2023
In type 1 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA<sub>1c</sub> at 26 wkMichael J Lockhart, Sean F DinneenAnnals of Internal Medicine|March 1, 2021
In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA<sub>1c</sub> or significant/severe hypoglycemiaTomás P Griffin, Sean F DinneenAnnals of Internal Medicine|May 3, 2021
In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DMTomás P Griffin, Sean F DinneenAnnals of Internal Medicine|October 19, 2020
SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetesTomás P Griffin, Sean F DinneenDiabetes/Metabolism Research and Reviews|October 11, 2015
In-hospital metabolic regulation in patients with a diabetic foot ulcer: is it worthwhile?Aoife M Egan, Sean F DinneenAnnals of Internal Medicine|April 6, 2026
In adults with T1D and overweight or obesity, adding GLP-1 RAs to insulin reduces weight, HbA<sub>1c</sub> levels, and insulin doseDavid J McDonnell, Sean F Dinneen, Annals of Internal Medicine|July 3, 2023
In type 2 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA<sub>1c</sub> at 26 wkMichael J Lockhart, Sean F DinneenPageof 6